Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucero-Acuña, Armando, Jeffery, Justin J, Abril, Edward R, Nagle, Raymond B, Guzman, Roberto, Pagel, Mark D, Meuillet, Emmanuelle J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263440/
https://www.ncbi.nlm.nih.gov/pubmed/25516710
http://dx.doi.org/10.2147/IJN.S68511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263440/
https://www.ncbi.nlm.nih.gov/pubmed/25516710
http://dx.doi.org/10.2147/IJN.S68511

Ejemplares similares